Clinical Trial Update: Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults [Phase 1]

View source ↗

Summary

This Phase 1 trial assesses safety and immunogenicity of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in flavivirus-naïve adults, with results now posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Zika Virus Infection

Drugs mentioned

• rZIKV/D4Δ30-713 (live attenuated Zika vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Zika Virus | Phase 1 | Status: COMPLETED | Results posted: 2025-08-05